Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 3,220,000 shares, an increase of 21.1% from the August 15th total of 2,660,000 shares. Currently, 9.2% of the company’s stock are short sold. Based on an average trading volume of 239,500 shares, the days-to-cover ratio is presently 13.4 days.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
Several hedge funds have recently added to or reduced their stakes in BCLI. AIGH Capital Management LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter valued at $4,815,000. Renaissance Technologies LLC purchased a new position in shares of Brainstorm Cell Therapeutics during the second quarter worth about $426,000. Liberty Wealth Management LLC acquired a new stake in shares of Brainstorm Cell Therapeutics during the first quarter worth about $496,000. Marshall Wace LLP purchased a new stake in shares of Brainstorm Cell Therapeutics in the 2nd quarter valued at about $139,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Brainstorm Cell Therapeutics by 27.5% in the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after purchasing an additional 53,036 shares during the period. 20.97% of the stock is currently owned by hedge funds and other institutional investors.
Brainstorm Cell Therapeutics Price Performance
NASDAQ:BCLI opened at $0.96 on Friday. Brainstorm Cell Therapeutics has a 12 month low of $0.95 and a 12 month high of $4.56. The firm has a market capitalization of $43.41 million, a PE ratio of -1.30 and a beta of -0.51. The business’s fifty day moving average price is $1.63 and its 200 day moving average price is $2.20.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a report on Thursday, August 17th. They set a “hold” rating for the company.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 9/11 – 9/15
- Your Comprehensive Guide to Investing in Bank Stocks
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.